Gainers

• Intellia Therapeutics (NASDAQ:NTLA) stock rose 19.1% to $16.23 during Friday's after-market session. The market value of their outstanding shares is at $1.8 billion.
• Compass Therapeutics (NASDAQ:CMPX) stock moved upwards by 12.32% to $5.65. The company's market cap stands at $716.8 million.
• CDT Equity (NASDAQ:CDT) stock rose 9.09% to $3.0. The market value of their outstanding shares is at $14.3 million.
• GT Biopharma (NASDAQ:GTBP) stock rose 8.8% to $0.34. The company's market cap stands at $9.5 million.
• SenesTech (NASDAQ:SNES) shares moved upwards by 8.49% to $1.66. The market value of their outstanding shares is at $8.1 million.
• Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 6.14% to $0.39. The market value of their outstanding shares is at $87.6 million.

Losers

• Armata Pharmaceuticals (AMEX:ARMP) stock declined by 9.1% to $11.75 during Friday's after-market session. The market value of their outstanding shares is at $495.6 million.
• iTonic Holdings (NASDAQ:ITOC) shares declined by 8.51% to $0.34. The market value of their outstanding shares is at $5.1 million.
• Cosmos Health (NASDAQ:COSM) stock fell 7.3% to $0.35. The market value of their outstanding shares is at $18.1 million.
• BNB Plus (NASDAQ:BNBX) shares declined by 6.57% to $0.48. The company's market cap stands at $2.8 million.
• Galmed Pharmaceuticals (NASDAQ:GLMD) shares declined by 5.56% to $0.59. The market value of their outstanding shares is at $4.0 million.
• Alpha Compute (NASDAQ:ALP) stock declined by 5.45% to $0.2. The company's market cap stands at $4.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.